336 related articles for article (PubMed ID: 31010682)
1. A novel antibody-drug conjugate, HcHAb18-DM1, has potent anti-tumor activity against human non-small cell lung cancer.
Huhe M; Lou J; Zhu Y; Zhao Y; Shi Y; Wang B; Sun X; Zhang X; Zhang Y; Chen ZN
Biochem Biophys Res Commun; 2019 Jun; 513(4):1083-1091. PubMed ID: 31010682
[TBL] [Abstract][Full Text] [Related]
2. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
[TBL] [Abstract][Full Text] [Related]
3. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
Cretella D; Saccani F; Quaini F; Frati C; Lagrasta C; Bonelli M; Caffarra C; Cavazzoni A; Fumarola C; Galetti M; La Monica S; Ampollini L; Tiseo M; Ardizzoni A; Petronini PG; Alfieri RR
Mol Cancer; 2014 Jun; 13():143. PubMed ID: 24898067
[TBL] [Abstract][Full Text] [Related]
4. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
[TBL] [Abstract][Full Text] [Related]
5. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
[TBL] [Abstract][Full Text] [Related]
7. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
8. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
[TBL] [Abstract][Full Text] [Related]
9. A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies.
Deckert J; Park PU; Chicklas S; Yi Y; Li M; Lai KC; Mayo MF; Carrigan CN; Erickson HK; Pinkas J; Lutz RJ; Chittenden T; Lambert JM
Blood; 2013 Nov; 122(20):3500-10. PubMed ID: 24002446
[TBL] [Abstract][Full Text] [Related]
10. Preclinical Evaluation of
Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
[TBL] [Abstract][Full Text] [Related]
11. Production and characterization of a camelid single domain anti-CD22 antibody conjugated to DM1.
Ziaei V; Ghassempour A; Davami F; Azarian B; Behdani M; Dabiri H; Habibi-Anbouhi M
Mol Cell Biochem; 2024 Mar; 479(3):579-590. PubMed ID: 37129769
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers.
Kelly MP; Hickey C; Makonnen S; Coetzee S; Jalal S; Wang Y; Delfino F; Shan J; Potocky TB; Chatterjee I; Andreev J; Kunz A; D'Souza C; Giurleo JT; Nittoli T; Trail PA; Thurston G; Kirshner JR
Mol Cancer Ther; 2017 Jul; 16(7):1299-1311. PubMed ID: 28377489
[TBL] [Abstract][Full Text] [Related]
13. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
[TBL] [Abstract][Full Text] [Related]
14. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
[TBL] [Abstract][Full Text] [Related]
15. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
Hamblett KJ; Le T; Rock BM; Rock DA; Siu S; Huard JN; Conner KP; Milburn RR; O'Neill JW; Tometsko ME; Fanslow WC
Mol Pharm; 2016 Jul; 13(7):2387-96. PubMed ID: 27248573
[TBL] [Abstract][Full Text] [Related]
16. Design of Coltuximab Ravtansine, a CD19-Targeting Antibody-Drug Conjugate (ADC) for the Treatment of B-Cell Malignancies: Structure-Activity Relationships and Preclinical Evaluation.
Hong EE; Erickson H; Lutz RJ; Whiteman KR; Jones G; Kovtun Y; Blanc V; Lambert JM
Mol Pharm; 2015 Jun; 12(6):1703-16. PubMed ID: 25856201
[TBL] [Abstract][Full Text] [Related]
17. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
18. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors.
Ab O; Whiteman KR; Bartle LM; Sun X; Singh R; Tavares D; LaBelle A; Payne G; Lutz RJ; Pinkas J; Goldmacher VS; Chittenden T; Lambert JM
Mol Cancer Ther; 2015 Jul; 14(7):1605-13. PubMed ID: 25904506
[TBL] [Abstract][Full Text] [Related]
19. Improved Tumor Penetration and Single-Cell Targeting of Antibody-Drug Conjugates Increases Anticancer Efficacy and Host Survival.
Cilliers C; Menezes B; Nessler I; Linderman J; Thurber GM
Cancer Res; 2018 Feb; 78(3):758-768. PubMed ID: 29217763
[TBL] [Abstract][Full Text] [Related]
20. Antibody-DM1 conjugates as cancer therapeutics.
Lopus M
Cancer Lett; 2011 Aug; 307(2):113-8. PubMed ID: 21481526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
